Excessos e alternativas da saúde mental na atenção primária

Autores

  • Alberto Ortiz Lobo Presidente de las Comisiones de Salud Mental y Prevención Cuaternaria, FAMFyG. Presidente del Capítulo de Salud Mental en APS de la Asociación de Psiquiatras Argentinos.
  • Jorge Bernstein Presidente de las Comisiones de Salud Mental y Prevención Cuaternaria, FAMFyG. Presidente del Capítulo de Salud Mental en APS de la Asociación de Psiquiatras Argentinos.

DOI:

https://doi.org/10.5712/rbmfc10(35)1055

Palavras-chave:

Saúde Mental, Efeitos adversos, Doença Iatrogênica, Medicalização, Prevenção Quaternária

Resumo

A extraordinária expansão da psiquiatria e da psicologia está proporcionando o tratamento de pessoas saudáveis que acabam sendo rotuladas como transtornos mentais. O reducionismo biológico do modelo médico centrado em sintomas favorece a transformação de problemas sociais em conflitos individuais e a exposição dos cidadãos aos efeitos adversos de tratamentos excessivos e inadequados. A prevenção quaternária em saúde mental contempla o uso de narrativas e formulação de casos (para além do rótulo diagnóstico), a indicação de não-tratamento e um uso prudente de drogas psicoativas, que leve em consideração sua desprescrição.

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...

Referências

Ortiz Lobo A. Hacia una psiquiatría crítica. Madrid: Editorial Grupo 5; 2013.

Ortiz Lobo A, González R, Rodríguez F. La derivación a salud mental de pacientes sin un trastorno psíquico diagnosticable. Aten Primaria. 2006;38(10):563-9. DOI: https://doi.org/10.1157/13095928

Thombs BD, Ziegelstein RC. Does depression screening improve depression outcomes in primary care? BMJ 2014;348:g1253. DOI: https://doi.org/10.1136/bmj.g1253

Gilbody S, House AO, Sheldon TA. Instrumentos de cribaje (screening) y detección de casos para la depresión (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. - See more at: http://es.summaries.cochrane.org/cd002792/instrumentos-de-cribaje-screening-y-deteccion-de-casos-para-la-depresion#sthash.tzlJquDm.dpuf

Rendueles G. Psiquiatrización de la ética - Ética de la psiquiatría: el idiota moral. In Ética y praxis psiquiátrica (ed Santander F). Madrid: AEN Colección Estudios; 2000.

Jervis G. Manual crítico de psiquiatría. Barcelona: Anagrama; 1977.

Hart JT. The inverse care law. Lancet, 1971; 1: 405-412. DOI: https://doi.org/10.1016/S0140-6736(71)92410-X

Allen Frances ¿Somos todos enfermos mentales? Buenos Aires: Ariel; 2014.

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):593-602. DOI: https://doi.org/10.1001/archpsyc.62.6.593

Bruce Arroll et al. Antidepresivos versus placebo para la depresión en la atención primaria (Revision Cochrane traducida). En: Biblioteca Cochrane Plus 2009 Número 3. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2009 Issue 3 Art no. CD007954. Chichester, UK: John Wiley & Sons, Ltd.).

Timimi S. Campaign to Abolish Psychiatric diagnosic Systems such as ICD and DSM (CAPSID) http://www.criticalpsychiatry.net/wp-content/uploads/2011/05/CAPSID12.pdf

Boisvert CM, Faust D. Iatrogenic symptoms in psychotherapy: A theoretical exploration of the potential impact of labels, language, and belief systems. American Journal of Psychotherapy 2002; 56: 244-260. DOI: https://doi.org/10.1176/appi.psychotherapy.2002.56.2.244

Crown S. Contraindications and dangers of psychotherapy. British Journal of Psychiatry 1983; 143: 436-441. DOI: https://doi.org/10.1192/bjp.143.5.436

Fernández Liria A, Rodríguez Vega B. La práctica de la psicoterapia. La construcción de narrativas terapéuticas. Bilbao: Desclée De Brower; 2001.

Bracken P et al. La Psiquiatría más allá del paradigma actual. Acta Psiquiátr Psicol Am Lat 2013; 59(3): 186-195, traducción de British Journal of Psychiatry. 2012; 201 :430-34.

Moos R. Iatrogenic effects of psychosocial interven- tions for substance use disorders: prevalence, predictors, prevention. Addiction 2005; 5: 595. DOI: https://doi.org/10.1111/j.1360-0443.2005.01073.x

Mohr. Negative outcome in psychotherapy: A critical review. Clinical Psychology: Science and Practice 1995; 2: 1-27. DOI: https://doi.org/10.1111/j.1468-2850.1995.tb00022.x

Lilienfeld, S. O. Psychological treatments that cause harm. Perspectives on Psychological Science 2007; 2: 53–70. DOI: https://doi.org/10.1111/j.1745-6916.2007.00029.x

Rose SC et al. Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD000560 DOI: https://doi.org/10.1002/14651858.CD000560

Currier JM, Holland JM, Neimeyer RA. The Effectiveness of Bereavement Interventions With Children: A Meta-Analytic Review of Controlled Outcome Research. Journal of Clinical Child Adolescent Psychology 2007; 36 (2): 253-259 DOI:10.1080/15374410701279669 DOI: https://doi.org/10.1080/15374410701279669

Currier JM, Neimeyer RA, Berman JS. The effectiveness of psychotherapeutic interventions for bereaved persons: A comprehensive quantitative review. Psychological Bulletin, Vol 134(5), Sep 2008, 648-661. doi: 10.1037/0033-2909.134.5.648 DOI: https://doi.org/10.1037/0033-2909.134.5.648

Moncrieff J, Cohen D. Rethinking models of psychotropic drug action. Psychother Psychosom 2005; 74:145- 153. DOI: https://doi.org/10.1159/000083999

Healy D. The creation of psychopharmacology. Cambridge MA: Harvard University Press; 2002. DOI: https://doi.org/10.4159/9780674038455

Bola JR, Mosher LR. Predicting Drug-Free Treatment Response in Acute Psychosis from the Soteria Project. Schizophr Bull 2002; 28(4):559-575. DOI: https://doi.org/10.1093/oxfordjournals.schbul.a006964

Seikkula J, Aaltonen J Alakare B, Haarakangas K, Keranen J, Lehtinen K. Five-year experience of first-episode nonaffective pychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies. Psychother Res 2006; 16(2): 214-228. DOI: https://doi.org/10.1080/10503300500268490

Husa AP, Rannikko I, Moilanen J, Haapea M, Murray GK, Barnett J, et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia—An observational 9-year follow-up study. Schizophrenia research 2014; 158(1), 134-141. DOI: https://doi.org/10.1016/j.schres.2014.06.035

Frota LH. Partial Agonists in the Schizophrenia Armamentarium. Tardive Dysphrenia: The newest challenge to the last generation atypical antipsychotics drugs? J Bras Psiquiatr 2003; 52 (Suppl 1): 14–24.

Fernandez HH. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord 2005; 20(1): 104-5. DOI: https://doi.org/10.1002/mds.20260

Margolese HC. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2002; 22(4): 347-52. DOI: https://doi.org/10.1097/00004714-200208000-00003

Chouinard G, Chouinard VA. Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes. Psychother Psychosom 2008;77:69-77 DOI: https://doi.org/10.1159/000112883

Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal related relapse. Acta Psychiatr Scand 2006;114:3-13 DOI: https://doi.org/10.1111/j.1600-0447.2006.00787.x

Ho BC, Andreasen NC, Ziebell S, Pierson R, Mag- notta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011; 68(2):128-37. DOI: https://doi.org/10.1001/archgenpsychiatry.2010.199

Veijola J, Guo JY, Moilanen JS, Jääskeläinen E, Miettunen J, et al. (2014) Longitudinal Changes in Total Brain Volume in Schizophrenia: Relation to Symptom Severity, Cognition and Antipsychotic Medication. PLoS ONE 9(7): e101689. doi:10.1371/journal.pone.0101689 DOI: https://doi.org/10.1371/journal.pone.0101689

Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005; 18 (3): 249-255. DOI: https://doi.org/10.1097/01.yco.0000165594.60434.84

Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, Pariente A, Bégaud B. Benzodiazepine use and risk of Alzheimer’s disease: case-control study BMJ 2014;349:g5205. DOI: https://doi.org/10.1136/bmj.g5205

Fava, G. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry 2003; 64:123-33 DOI: https://doi.org/10.4088/JCP.v64n0204

Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358(3): 252–260. DOI: https://doi.org/10.1056/NEJMsa065779

Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5(2): e45. DOI: https://doi.org/10.1371/journal.pmed.0050045

Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and Effectiveness of Antidepressants: Current Status of Research. Psychother Psychosom 2010; 79: 267–27 DOI: https://doi.org/10.1159/000318293

Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J. Antidepressant Drug Effects and Depression Severity. A Patient-Level Meta-analysis. JAMA 2010; 303(1):47-53. DOI: https://doi.org/10.1001/jama.2009.1943

Barbui C, Cipriani A, Patel V, Ayuso-Mateos JL, van Ommeren M.Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta- analysis. Br J Psychiatry 2011; 198(1):11-6 DOI: https://doi.org/10.1192/bjp.bp.109.076448

Gøtzsche P. Medicamentos que matan y crimen organizado. Barcelona: Ed. Los libros del lince; 2014.

Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. BMJ 2011;343:doi:10.1136/bmj.d4551 (Published 2 August 2011). DOI: https://doi.org/10.1136/bmj.d4551

Cortés Morales, B. Síndrome metabólico y antipsicóticos de segunda generación. Rev Asoc Esp Neuropsiquiatr 2011; 31 (110): 303-320. DOI: https://doi.org/10.4321/S0211-57352011000200009

Wang P et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications NEJM 2005; 353(22):2335-2341

Ballard C et al. The dementia antipsychotic withdrawal trial (DARTAD): long-term follow-up of a randomized placebo-controlled trial. Lancet Neurology 2009;8(2):151-7 DOI: https://doi.org/10.1016/S1474-4422(08)70295-3

Cosgrove L, Bursztajn HL, Krimsky S, Anaya M, Walker J. Conflicts of Interest and Disclosure in the American Psychiatric Association’s Clinical Practice Guidelines. Psychother Psychosom 2009; 78:228–232 DOI: https://doi.org/10.1159/000214444

Launer JA. Narrative approach to mental health in general practice BMJ 1999;318:117-9 DOI: https://doi.org/10.1136/bmj.318.7176.117

Mata Ruiz I, Ortiz Lobo A. Formulación de casos en salud mental: una guía de entrenamiento. En: Trastornos mentales comunes: manual de orientación. Madrid: Asociación Española de Neuropsiquiatría. Estudios 41; 2009.

Ortiz-Lobo A, Murcia-García L. La indicación de no-tratamiento: aspectos psicoterapéuticos. En: Trastornos mentales comunes: manual de orientación. Madrid: Asociación Española de Neuropsiquiatría. Estudios 41; 2009

Schiff GD et al. Principles of conservative prescribing. Arch Intern Med 2011;256v1 DOI: https://doi.org/10.1001/archinternmed.2011.256

Publicado

2015-06-24

Como Citar

1.
Ortiz Lobo A, Bernstein J. Excessos e alternativas da saúde mental na atenção primária. Rev Bras Med Fam Comunidade [Internet]. 24º de junho de 2015 [citado 28º de março de 2024];10(35):1-9. Disponível em: https://rbmfc.org.br/rbmfc/article/view/1055

Plaudit